Literature DB >> 34400172

Tau phosphorylation and OPA1 proteolysis are unrelated events: Implications for Alzheimer's Disease.

Marcel V Alavi1.   

Abstract

The neuropathological hallmarks of Alzheimer's Disease are plaques and neurofibrillary tangles. Yet, Alzheimer's is a complex disease with many contributing factors, such as energy-metabolic changes, which have been documented in autopsy brains from individuals with Alzheimer's and animal disease models alike. One conceivable explanation is that the interplay of age-related extracellular and intracellular alterations pertaining to Alzheimer's, such as cerebrovascular changes, protein aggregates and inflammation, evoke a mitochondrial response. However, it is not clear if and how mitochondria can contribute to Alzheimer's pathophysiology. This study focuses on one particular aspect of this question by investigating the functional interaction between the microtubule-associated protein tau and the mitochondrial inner membrane fusion machinery, which shows alterations in Alzheimer's brains. OPA1 is an essential inner membrane-fusion protein regulated by the two membrane proteases OMA1 and YME1L1. Assessment of OPA1 proteolysis-usually found in dividing mitochondria-and posttranslational tau modifications in mouse and human neuroblastoma cells under different experimental conditions clarified the relationship between these two pathways: OPA1 hydrolysis and phosphorylation or dephosphorylation of tau may coincide, but are not causally related. OPA1 cleavage did not alter tau's phosphorylation pattern. Conversely, tau's phosphorylation state did not induce nor correlate with OPA1 proteolysis. These results irrefutably demonstrate that there is no direct functional interaction between posttranslational tau modifications and the regulation of the OMA1-OPA1 pathway, which implies a common root cause modulating both pathways in Alzheimer's.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer's; Fusion.; Mitochondria; OMA1; Tau hyperphosphorylation

Mesh:

Substances:

Year:  2021        PMID: 34400172      PMCID: PMC8525314          DOI: 10.1016/j.bbamcr.2021.119116

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  107 in total

Review 1.  Abnormalities of mitochondrial enzymes in Alzheimer disease.

Authors:  G E Gibson; K F Sheu; J P Blass
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

2.  Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:ubiquinone oxidoreductase).

Authors:  J G Okun; P Lümmen; U Brandt
Journal:  J Biol Chem       Date:  1999-01-29       Impact factor: 5.157

3.  Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics.

Authors:  C Bialojan; A Takai
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

4.  Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease.

Authors:  Jin-Jing Pei; Cheng-Xin Gong; Wen-Lin An; Bengt Winblad; Richard F Cowburn; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 5.  Treatment Options in Alzheimer´s Disease: The GABA Story.

Authors:  Maite Solas; Elena Puerta; Maria J Ramirez
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

6.  Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A.

Authors:  G Drewes; E M Mandelkow; K Baumann; J Goris; W Merlevede; E Mandelkow
Journal:  FEBS Lett       Date:  1993-12-28       Impact factor: 4.124

7.  Uncoupling of mitochondria activates protein phosphatases and inactivates MBP protein kinases.

Authors:  Yuan Luo; Vernon M. Ingram
Journal:  J Alzheimers Dis       Date:  2001-12       Impact factor: 4.472

Review 8.  Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis.

Authors:  Ian W Weidling; Russell H Swerdlow
Journal:  Exp Neurol       Date:  2020-04-25       Impact factor: 5.330

Review 9.  Targeting Apolipoprotein E for Alzheimer's Disease: An Industry Perspective.

Authors:  Georgette L Suidan; Gayathri Ramaswamy
Journal:  Int J Mol Sci       Date:  2019-05-01       Impact factor: 5.923

Review 10.  Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease.

Authors:  Amy F T Arnsten; Dibyadeep Datta; Kelly Del Tredici; Heiko Braak
Journal:  Alzheimers Dement       Date:  2020-10-19       Impact factor: 16.655

View more
  1 in total

Review 1.  Recent advances in, and challenges of, designing OMA1 drug screens.

Authors:  Marcel V Alavi
Journal:  Pharmacol Res       Date:  2022-01-07       Impact factor: 7.658

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.